Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Engineered mischarged transfer RNAs for correcting pathogenic missense mutations

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Homo sapiens

PROVIDER: GSE236624 | GEO | 2024/01/03

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Engineered mischarged transfer RNAs for correcting pathogenic missense mutations [mRNA-seq]

Project description:Missense mutations account for nearly 50% of pathogenic mutations in human genetic diseases, most lack effective treatments. Gene therapies, CRISPR-based gene editing, and RNA therapies including transfer RNA (tRNA) modalities are common strategies for potential treatments of genetic diseases. However, reported tRNA therapies are for nonsense mutations, how tRNAs can be engineered to correct missense mutations have not been explored. Here, we describe missense correcting tRNAs (mc-tRNAs) as a potential therapeutic modality for correcting pathogenic missense mutations. Mc-tRNAs are engineered tRNAs that are charged with one amino acid and read codons of another amino acid in translation in human cells. We first developed a series of fluorescence protein (FP)-based reporters that indicate successful correction of missense mutations via restoration of fluorescence signals. We engineered mc-tRNAs that effectively corrected Serine and Arginine missense mutations in the reporters and confirmed the amino acid substitution by protein mass spectrometry and mc-tRNA expression by tRNA sequencing. We examined the transcriptome response to the expression of mc-tRNAs and found some mc-tRNAs induced minimum transcriptomic changes. Furthermore, we applied an Arg-tRNAGln(CUG) mc-tRNA to rescue the autolytic activity of a pathogenic CAPN3 Arg-to-Gln mutant involved in limb-girdle muscular dystrophy type 2A. These results establish a versatile pipeline for mc-tRNA engineering and demonstrate the potential of mc-tRNA as an alternative therapeutic platform for the treatment of genetic disorders.

2024-01-04 | GSE236622 | GEO

Engineered mischarged transfer RNAs for correcting pathogenic missense mutations [MSR-seq]

2024-01-04 | GSE236623 | GEO

Engineered mischarged transfer RNAs for correcting pathogenic missense mutations

Project description:Engineered mischarged transfer RNAs for correcting pathogenic missense mutations

| PRJNA991914 | ENA

Engineered mischarged transfer RNAs for correcting pathogenic missense mutations [MSR-seq]

Project description:Engineered mischarged transfer RNAs for correcting pathogenic missense mutations [MSR-seq]

| PRJNA991918 | ENA

Engineered mischarged transfer RNAs for correcting pathogenic missense mutations [mRNA-seq]

Project description:Engineered mischarged transfer RNAs for correcting pathogenic missense mutations [mRNA-seq]

| PRJNA991919 | ENA

Coding mutations and loss-of-imprinting in human pluripotent cells derived by nuclear transfer and defined factors

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2014-11-06 | E-GEOD-61657 | biostudies-arrayexpress

Missense mutations in CRX homeodomain cause dominant retinopathies through two distinct mechanisms

Project description:This SuperSeries is composed of the SubSeries listed below.

2023-11-08 | GSE223659 | GEO

Efficient suppression of endogenous CFTR nonsense mutations using anticodon-engineered transfer RNAs.

Project description:Nonsense mutations or premature termination codons (PTCs) comprise ∼11% of all genetic lesions, which result in over 7,000 distinct genetic diseases. Due to their outsized impact on human health, considerable effort has been made to find therapies for nonsense-associated diseases. Suppressor tRNAs have long been identified as a possible therapeutic for nonsense-associated diseases; however, their ability to inhibit nonsense-mediated mRNA decay (NMD) and support significant protein translation from endogenous transcripts has not been determined in mammalian cells. Here, we investigated the ability of anticodon edited (ACE)-tRNAs to suppress cystic fibrosis (CF) causing PTCs in the cystic fibrosis transmembrane regulator (CFTR) gene in gene-edited immortalized human bronchial epithelial (16HBEge) cells. Delivery of ACE-tRNAs to 16HBEge cells harboring three common CF mutations G542XUGA-, R1162XUGA-, and W1282XUGA-CFTR PTCs significantly inhibited NMD and rescued endogenous mRNA expression. Furthermore, delivery of our highly active leucine-encoding ACE-tRNA resulted in rescue of W1282X-CFTR channel function to levels that significantly exceed the necessary CFTR channel function for therapeutic relevance. This study establishes the ACE-tRNA approach as a potential standalone therapeutic for nonsense-associated diseases due to its ability to rescue both mRNA and full-length protein expression from PTC-containing endogenous genes.

| S-EPMC9126842 | biostudies-literature

A missense mutation in TFRC, encoding transferrin receptor 1, causes combined immunodeficiency

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2015-11-25 | E-GEOD-75358 | biostudies-arrayexpress

Correcting Direct Effects of Ethanol on Translation and Transcription Machinery Confers Ethanol Tolerance in Bacteria

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2014-06-18 | E-GEOD-56408 | biostudies-arrayexpress